Medical Professionals Demand STI Classification for Widespread Women's Infection
If you are sexually active, you are likely familiar with common sexually transmitted infections such as chlamydia, gonorrhoea, and syphilis. However, doctors are now pushing for a significant change that would add another condition to this list. Bacterial vaginosis, a prevalent infection affecting approximately one billion women globally, is at the centre of a campaign to be reclassified as a sexually transmitted infection in the United Kingdom.
Scope of the Issue and Medical Advocacy
Bacterial vaginosis impacts around 11 million women in the UK, with about one-third experiencing it at least once during their lifetime. The infection results from an imbalance in the natural bacterial environment of the vagina. Leading the charge for updated guidelines is Valentina Milanova, a gynaecologist and founder of the gynaecological health brand Daye. She emphasizes the urgent need for action, noting that sexual activity or changing partners can trigger the condition.
While men cannot contract bacterial vaginosis themselves, they can harbour the bacteria responsible for causing the infection in women, Dr Milanova explains. She challenges the traditional view that has prevented its classification as an STI, stating, 'The argument against calling bacterial vaginosis an STI is that it involves an overgrowth of natural flora rather than a single external pathogen. However, this position is increasingly difficult to defend.'
Evidence Supporting Sexual Transmission
The push for reclassification gained substantial momentum from a landmark 2025 trial published in the New England Journal of Medicine. This study demonstrated that treating male partners alongside women with bacterial vaginosis led to significantly higher cure rates. Dr Milanova highlights, 'This provides the strongest evidence to date that bacterial vaginosis is sexually transmissible. Reinfection is a key factor in its high recurrence rate, which can reach up to 50% within six months.'
UK Lagging Behind International Standards
Dr Milanova points out that the UK is an outlier in this regard. Countries such as Australia, the United States, and Canada already manage bacterial vaginosis within their STI frameworks and treatment protocols. Similarly, the World Health Organization includes it in this category, and the American College of Obstetrics and Gynaecology began recommending partner treatment for recurrent and symptomatic cases in late 2025.
'The UK is an outlier,' Dr Milanova asserts, noting that the British Association for Sexual Health and HIV's guidelines on bacterial vaginosis have not been updated since 2012. This delay means clinicians are not routinely treating partners, notifying contacts, or conducting systematic screenings, leaving many women trapped in a cycle of recurrence that affects their overall wellbeing.
Understanding Bacterial Vaginosis
Bacterial vaginosis is a common condition that disrupts the vaginal microbiome, characterized by a decrease in beneficial lactobacilli and an overgrowth of other bacteria. While it can be asymptomatic, about half of affected women experience symptoms, which according to the World Health Organization include:
- Unusual vaginal discharge
- A strong fishy or musty odour from the vagina
- Itching or irritation around the vagina
- Burning during urination
Although often not serious, untreated bacterial vaginosis can lead to complications during pregnancy, such as miscarriage or premature birth. It also increases the risk of contracting other STIs, including HIV, and can contribute to pelvic inflammatory disease.
Causes and Risk Factors
The exact cause of bacterial vaginosis remains unclear, but risk factors include being sexually active, changing sexual partners, using an intrauterine device, or applying perfumed products in or around the vagina.
Medical Perspectives on Classification
Dr Giuseppe Aragona, a GP and medical advisor for Prescription Doctor, offers a nuanced view. He suggests that whether bacterial vaginosis should be formally reclassified as an STI depends on how strictly one defines the term. 'While there is growing evidence of sexual transmission dynamics and partner involvement in recurrence, it does not behave like a classic STI in terms of a single causative organism or straightforward transmission pattern,' he explains.
Dr Aragona proposes that it might be more accurately described as a 'sexually associated dysbiosis,' referring to a bacterial imbalance typically induced by sexual activity. However, he acknowledges, 'I can understand why some clinicians argue that recognizing its sexual transmissibility more explicitly could improve prevention strategies and partner management.'
Katy Jackson, clinical director of women's health at Voy, notes that while there are no current developments within the NHS to classify bacterial vaginosis as an STI, experts are beginning to suggest it should be managed as one.
Potential Implications of Reclassification
If bacterial vaginosis were officially labelled as an STI in the UK, Dr Aragona predicts it would 'become one of the most prevalent diagnosed conditions in sexual health services.' Dr Jackson adds that it would be more common than chlamydia or gonorrhoea, though it is not currently included in STI statistics due to its classification.
This change could significantly impact service demand, screening practices, and public awareness. Dr Aragona explains, 'It could potentially reduce diagnostic delay and encourage more consistent consideration of partner factors in recurrence. However, it could also risk over-medicalisation or stigma if not framed carefully.'
Reclassification might shift treatment pathways toward more partner-inclusive approaches and emphasize recurrence prevention. This could reduce the reliance on repeated short courses of antibiotics. Dr Aragona theorizes that such a label could also drive research funding into emerging areas like microbiome restoration therapies and vaccine-like approaches.
Conclusion
The debate over classifying bacterial vaginosis as an STI highlights evolving understandings of sexual health. With compelling evidence supporting sexual transmission and partner treatment efficacy, medical professionals are urging the UK to align with international standards. This potential reclassification promises to enhance prevention strategies, improve treatment outcomes, and address the high recurrence rates affecting millions of women, ultimately fostering better holistic wellbeing and advancing research in women's health.
